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We report the derivation and characterization of two new human embryonic stem cells (hESC) lines (CU1 and CU2) from
embryos with an irreversible loss of integrated organismic function. In addition, we analyzed retrospective data of morphological
progression from embryonic day (ED) 5 to ED6 for 2480 embryos not suitable for clinical use to assess grading criteria indicative
of loss of viability on ED5. Our analysis indicated that a large proportion of in vitro fertilization (IVF) embryos not suitable for
clinicaluse could be used for hESC derivation. Based on these combined ﬁndings, we propose that criteria commonlyused in IVF
clinics to determine optimal embryos for uterine transfer can be employed to predict the potential for hESC derivation from poor
quality embryos without the destruction of vital human embryos.
1.Introduction
Humanembryonicstemcells(hESCs)aretheultimatemodel
for in vitro study of cell growth and diﬀerentiation and the
most promising candidates for cell therapy in regenerative
medicine due to their high proliferative capacity and ability
to diﬀerentiate into lineages of all three embryonic germ
layers [1]. hESCs are rapidly emerging as valuable screening
platforms for drug toxicity and tools for drug discovery [2–
4].
Recent advances in generation of induced pluripotent
stem (iPS) cells [5–8] have shifted focus from hESC to iPS
cells as more likely candidates for clinical use, as they have
the potential to generate patient-speciﬁc therapy and avoid
the unwanted immune response in the host [5]. However,
in a recent study the question of developmental equivalence
between hESC and human iPS cells was raised. Using gene
expressionproﬁling,itwasdemonstratedthatdespitethefact
that hESC and human iPS cells share pluripotency markers,
their expression signatures are distinct [9]. It is unresolved
whether the small percentage of genes that is diﬀerentially
expressed could result in a biologically signiﬁcant diﬀerence
[5, 10]. Importantly, two recent studies demonstrated that
iPS cells retain an epigenetic memory relating to their cells
of origin that restricts their diﬀerentiation potential [11,
12]. While iPS cell technology does seem a very promising
avenue for bringing stem cell therapy to the bedside, it is
important to continue studying hESC, because it is diﬃcult
topredictwhetherhESCoriPS cellswill bemoreeﬀectivefor
therapeutic application.
hESC lines are conventionally derived from the inner cell
mass (ICM) of viable human preimplantation embryos. Our
group has proposed one of several strategies for derivation
of hESC without the destruction of viable embryos [13].2 Stem Cells International
During routine in vitro fertilization (IVF) procedures, a
large proportion of embryos fail to developproperly [14–16]
and are discarded because they are unsuitable for embryo
transfer [17, 18]. We and others have found that many of
these embryos have suﬀered an irreversible loss of integrated
organismic function and have deﬁned them on that basis
as nonviable or organismically dead [19, 20]. In our study,
such ED6 embryos did not progress upon extended in
vitro culture although more than 80% of them contained
living cells as assessed by the use of vital dyes [20]. Thus,
we have proposed that hESC lines could be derived from
these nonviable embryos and have suggested that ethical
guidelines for essential organ donation could be employed
for the clinical application of this paradigm [13, 20–22].
To date, two groups have successfully derived hESC from
poor quality embryos that were nonviable by our criteria.
In the ﬁrst report, a single, stable hESC line was derived
from 132 arrested embryos [23], and in the second, eleven
lines were derived from 413 poor quality embryos rejected
for clinical use [24]. All 12 hESC lines were karyotypically
normal and pluripotency and their diﬀerentiation potential
was demonstrated both in vitro and in vivo.
Our objectives were ﬁrst to extend this work by deriving
new hESC lines from discarded, nonviable embryos at
ED6 and secondly to deﬁne morphological criteria for
nonviabilityadayearlier,onED5,inordertoallowtheearlier
derivation of hESC when a greater number of viable cells are
likely to be present. Here, we describe two new hESC lines
derived from nonviable ED6 embryos and in a retrospective
study identify a subgroup of nonviable, cavitated embryos
withthepotentialtoyieldhESClines.Bytargetingderivation
eﬀorts on this subgroup, derivation success rate might be
increased.
2.Materialsand Methods
2.1. Feeder Cells and Culture Media. Commercial irradiated
CF1 mouse embryo ﬁbroblasts (MEFs)(Global Stem Cell,
Rockville, MD) were plated on 0.1% gelatin (Sigma Aldrich,
St Louis, MO) coated 4-well dishes (NUNC, Rochester, NY)
at 150,000 cells per well. MEFs were cultured in MEF media
consisting of DMEM (Invitrogen, Carlsbad, CA), 10% FBS
(Hyclone, Logan, UT), 100mM L-glutamine (Invitrogen),
and 1% penicillin/streptomycin (Invitrogen).
hESC derivation media consisted of Knockout DMEM
(Invitrogen), 17% Knockout Serum Replacement (KSR,
Invitrogen) with 3% FBS (Hyclone), 10ng/mL bFGF (Invit-
rogen), 100µM beta-mercaptoethanol (Invitrogen), 100mM
nonessential amino acids (Invitrogen), 1mM L-glutamine
(Invitrogen), and 1% penicillin/streptomycin (Invitrogen).
hESCs were cultured in the same media with the exception
of 20% KSR, 20ng/mL bFGF, and no FBS. Quinn’s HEPES
medium (Q-HEPES) and Quinn’s Advantage Protein Plus
Blastocyst Medium (QBlast)(both from Sage Media, Cooper
Surgical, Pasadena, CA) were used for embryo recovery or
washes and short-term culture, respectively.
2.2. Embryos. Approvals were obtained from the Institu-
tional Review Board (IRB) and the Embryonic Research
Committee at Columbia University to collect nonviable
embryos. The embryos were generated by IVF for the pur-
pose of treating infertile couples with assisted reproduction
at the Center for Women’s Reproductive Care (CWRC). For
all embryos used in this study, patients’ written consent was
obtained prior to the IVF procedure and patients’ records
were deidentiﬁed. Patients agreed to allow research to be
performed upon any and all nonviable embryos destined to
be discarded. In total, 375 embryos from 87 patients were
declared nonviable and were available for this study. Only
embryos meeting criteria of nonviability were subject to
attempted hESC derivation.
Allpatientsunderwent routine controlled ovarian hyper-
stimulation with human gonadotropins to eﬀect follicle
growth and development. Oocyte retrieval, fertilization, and
assessment of embryo development were performed by
CWRC as previously described [20]. On embryonic day 6
(ED6),embryosthathadarrestedorfailedtodividenormally
were rejected for clinical use by the CWRC laboratory. They
were transported to the laboratory as previously described
[20] and used for hESC derivation.
2.3. Embryo Plating and Outgrowth Culture. Embryos were
recovered as previously described [20]a n dp l a c e di n2 0µL
drop cultures with QBlast. Assessment was performed under
phase and brightﬁeld optics to determine the morpholog-
ical categories [20] and to triage embryos for derivation.
Derivation was attempted only for 159 embryos that showed
signs of compaction and/or cavitation. These embryos were
treated with acid Tyrode’s (AT) (Sigma) solution to remove
the zona pellucida (ZP), washed brieﬂy in Q-HEPES and
plated onto dishes of inactivated MEFs in hESC derivation
media, and incubated at 37◦Ci n5 %C O 2 in air. Media
waschanged everysecondday.Outgrowthsdisplaying hESC-
likemorphologywere observed2–14dayspostplating. When
hESC lines were successfully established, hESC derivation
media was exchanged for hESC culture media to prevent
spontaneous diﬀerentiation. Initial passaging of outgrowths
and subsequent established hESC lines was carried out
by microdissection (“cut and paste” subculture). Typically,
microdissection was performed every 5–7 days; cystic and
diﬀerentiated material was removed and undiﬀerentiated
areas of colonies were cut into several pieces, collected by
aspiration and transferred onto fresh feeders.
2.4. Immunoﬂuorescence. hESC colonies and adhered em-
bryoid bodies were ﬁxed in Formalin-Free Fixative (Sigma)
or 3.7% formaldehyde in PBS for 20 minutes, permeabilized
with 0.1% Triton in PBS for 10 minutes for intracellular
stains and blocked with 10% goat/horse serum for 45
minutes. Cells were incubated with primary antibody at
room temperature for 1 hour, washed, and incubated with
an appropriate secondary antibody for 30 minutes. After
washing, the nuclei were stained with 4,6-diamidino-2-
phenylindole dilactate (DAPI, Invitrogen) for 2 minutes,
and the cultures were observed on a ﬂuorescent micro-
scope (IX81, Olympus, Center Valley, PA). Oct3/4 antibody,
neuron-speciﬁc beta-III tubulin (TuJ-1) antibody and goatStem Cells International 3
IgG secondary antibody were from R&D Systems (Min-
neapolis, MN). Stage-speciﬁc embryonic antigen-3 (SSEA-
3), SSEA-4, tumor rejection antigen 1–60 (TRA 1–60), TRA
1–81 antibodies, and mouse IgG/IgM secondary antibody
were from Chemicon/Millipore (Billerica, MA). Alpha-1-
fetoprotein (AFP) antibody was from DakoCytomation
(Glostrup, Denmark), and smooth muscle actin (SMA) anti-
body was from Invitrogen.
2.5.QuantitativeReal-Time Reverse-Transcription Polymerase
C h a i nR e a c t i o n( q R T - P C R ) .Total RNA was extracted from
hESC and embryoid bodies using RNeasy mini-kits (Qiagen,
Valencia, CA), followed by treatment with DNase (Invitro-
gen). Total RNA was reverse-transcribed into cDNA with
random hexamers using SuperScript III First-Strand Syn-
thesis System (Invitrogen). Expression of POU5F1/OCT4,
SOX2, NANOG, BRACHYURY, AFP and PAX6 was quan-
tiﬁed using the ABI Prism 7900 real-time system (Applied
Biosystems, Foster City, CA) and normalized to the expres-
sion of housekeeping gene glyceraldehyde-3-phosphate-de-
hydrogenase (GAPDH). Standard cycling conditions were
used for all assays (TaqMan chemistry, Applied Biosystems).
Primer sequences for the human NANOG gene [25]w e r e5  -
TGAGCTGGTTGCCTCATGTTAT-3  (forward primer), 5 -
GAAGGAAAAGTATCAAGAAATTGGGATA-3  (reverse
primer), 5 -ATGCAGGCAACTCA-3  (FAM/non-ﬂuores-
cent quencher labeled MGB probe) (Applied Bi-osystems).
Primers and probes for POU5F1/OCT4 (Hs00742896 s1),
SOX2(Hs00602736 s1),T/BRACHYURY (Hs00610080 m1),
AFP(Hs00173490 m1),PAX6 (Hs00240871 m1),andGAPDH
(4310884E, VIC/TAMRA labeled) were purchased from Ap-
plied Biosystems.
2.6. In Vitro Diﬀerentiation Assay. Near conﬂuent hESCs
were microdissected as described, transferred to nonadher-
ent plates and allowed to diﬀerentiate spontaneously by
embryoidbodyformationinKnockoutDMEM(Invitrogen),
supplemented with 20% FBS (Hyclone), 100µMb e t a -
mercaptoethanol (Invitrogen), 100mM nonessential amino
acids (Invitrogen), 1mM L-glutamine (Invitrogen), and
1% penicillin/streptomycin (Invitrogen). Embryoid bodies
were cultured up to 5 weeks with media change twice per
week. For gene expression analyses, embryoid bodies were
harvested on days 4, 8, 14, and 21. For immunoﬂuorescence,
embryoid bodies were transferred to gelatin-coated glass-
bottom culture dishes (MatTek, Ashland, MA) after 3 weeks
and cultured for an additional week to achieve diﬀerenti-
ated cell outgrowth. For histology, embryoid bodies were
harvested after 5 weeks, washed with PBS, ﬁxed in 3.7%
formaldehyde in PBS, and embedded in paraﬃn. Ten µm-
thick sections were stained with hematoxylin-eosin (HE) or
Masson’s trichrome.
2.7. In Vivo Diﬀerentiation Assay. For the generation of
teratomas,contentsoftwowellsofasubconﬂuent6-well dish
(approximately 105-106 cells) were subcutaneously injected
per mouse into the neck region of 4–6 weeks old SCID beige
mice (Harlan, Indianapolis, IN) (n = 4p e re x p e r i m e n t a l
group). Animals were palpated weekly for development of
tumors. 12 to 14 weeks postinjection, suspected tumors were
removed, ﬁxed in 4% paraformaldehyde or Bouin’s ﬁxative
solution and embedded in paraﬃn. Ten µm-thick sections
were stained with HE, Masson’s trichrome, or processed for
immunohistochemistry. All experiments involving labora-
tory animals were performed under protocols approved by
the Columbia University Institutional Animal Care and Use
Committee.
2.8. Karyotyping. Standard G-band karyotyping was per-
formed by Columbia University Cytogenetics Laboratory.
2.9. Retrospective ED5/ED6 Data. With IRB approval, de-
identiﬁed records of human embryos generated for IVF were
examined. Morphological progression from ED5 to ED6 was
analyzedretrospectively inembryosthatwerenotsuitablefor
clinical use on ED5 and were reevaluated on ED6. Embryos
transferred or cryopreserved on ED5 were also included in
theanalysis. Mostoftheembryosanalyzedwereingroupcul-
ture, thus morphological categories from ED5 and ED6 were
compared as cohort populations. Morphological categories
used in the CWRC for clinical grading on ED5 and ED6
were deg = degenerated (an embryo showing pronounced
signs of degeneration), frag = fragmented, 1C = single-celled
embryo (1C), MC = multicell (embryo containing 2 or more
blastomeres with or without cellular fragmentation), comp
= embryo showing some sign of compaction, EB = embryo
with a small cavity, the ﬁrst sign of blastocyst formation, B
= embryo with a large cavity and HB = hatching blastocyst,
embryo with a large cavity and at least one cell protruding
through the ZP. All embryos in categories B and HB, which
represent blastocyst formation, were given overall grades of
good, fair, or poor and in addition, the quality of inner cell
mass (ICM) and trophectoderm (TE) was graded from A
to D. This is in accordance with the American Society for
Reproductive Medicine/Section for Assisted Reproduction
Technologies blastocyst grading system, per standard CWRC
practice.
3.Results
3.1. Derivation and Characterization of New hESC Lines. In
our previous study, we categorized nonviable ED6 embryos
on the basis of gross morphology and determined the
number of vital and nonvital cells contained in each embryo
[20]. Although morphological categorization was generally
of limited value in predicting cell number, a higher number
of living cells was associated with cavitation, suggesting
that cavitation might predict greater potential for success
of hESC derivation. This is in line with a previous study
where derivation eﬃciency was lower for cleavage-arrested
embryos than for embryos arrested following cavitation
[26]. In preliminary experiments (data not shown), we
observed little or no attachment when early-arrested non-
viable embryos were plated on MEFs. Thus nonviable ED6
embryos were triaged using morphological categories as
previously described [20], and only embryos showing signs4 Stem Cells International
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Figure 1: Nonviable ED6 embryos, showing cavitation but either no or highly abnormal ICMs, initial outgrowths, and typical colony
appearance. Brightﬁeld images of embryos used for CU1 (a) and CU2 (b) hESC derivation. Phase contrast images of representative initial
outgrowthstwo (c),ﬁve (d), or14 days (e) postplating andtypical establishedhESC colonies(f, g, h). Scalebar = 20µm (a,b); 100µm( c – h ) .
of compaction and/or cavitation with no or an abnormal
ICM (159/375) were plated on MEFs to attempt hESC
derivation. Initial embryo outgrowths were observed from
2t o1 4d a y sa f t e rp l a t i n go nM E F s .I nt o t a l ,8 3e m b r y o s
gave rise to primary colonies (p0); of these 69 outgrowths
deteriorated prior to ﬁrst passaging, 14 survived the ﬁrst
passage, three survived the second passage, and two survived
the third passage and beyond, resulting in the hESC lines
CU1 and CU2 (Figure 1). BothCU1 and CU2 hESC colonies
display typical stem-cell-like morphology. Karyotype analy-
sis revealed a normal female karyotype for CU1 at passage
9. CU2 showed a normal female karyotype at passage 8
(46, XX) with a low level of mosaicism for chromosome 18
monosomy (3/31 cells; Supplementary Figure S1 available
online at doi: 10.4061/2011/765378). Self-renewal capacity
was demonstrated by successfully propagating both hESC
lines for more than 30 passages.
Characterization of CU1 and CU2 hESC lines demon-
strated the presence of speciﬁc hESC markers of the undif-
ferentiated state [25] such as transcription factor POU5F1/
OCT4, keratan surface antigens TRA-1–60 and TRA-1–81,
glycolipidantigenSSEA-4,andtheabsenceofglycolipidanti-
gen SSEA1, commonly expressed upon hESC diﬀerentiation
(Figure 2 and Supplementary Figure 2). Similar expression
of cell surface antigens was noted for the previously char-
acterized CHB1 line, established from a cleavage-arrested
poor quality embryo [26]. Quantitative real-time RT-PCR
was used to assess the expression of genes in undiﬀer-
entiated CU1 and CU2 hESC lines and in diﬀerentiated
embryoid bodies derived from them. The CHB1 line was
used as a control for comparison of gene expression levels
in undiﬀerentiated hESC and in diﬀerentiated embryoid
bodies (Figure 3). Quantitative real-time RT-PCR analysis
demonstrated similar or higher levels of expression of plu-
ripotency genes POU5F1/OCT4, NANOG,a n dSOX2 in
undifferentiated CU1 and CU2 cells when compared with
undifferentiated CHB1 line (Figure 3). Upon diﬀerentiation
into embryoid bodies, the expression of POU5F1/OCT4,
NANOG,a n dSOX2 was downregulated while the markers
ofdiﬀerentiationBRACHYURY (mesodermallineage);alpha
fetoprotein (AFP; endodermal lineage), and PAX6 (ectoder-
mal lineage) were upregulated in both CU1 and CU2 hESC
lines (Figure 3). Similarly, diﬀerentiated embryoid bodies
expressed neuron-speciﬁc beta-IIItubulin(TUJ-1),AFP,and
smooth muscle actin (SMA) as assessed by immunoﬂuo-
rescence (Figure 2 and Supplementary Figure 2). Both CU1
and CU2 lines diﬀerentiated into derivatives of all three
embryonic germ layers in vitro. CU1 and CU2 hESC were
injected into SCID beige mice (n = 4p e re x p e r i m e n t a l
group) and no palpable tumors were detected from 12 to
14 weeks postinjection. The analyses of suspected tumors
revealed the presence of hibernoma (3 out of 8) at the
site of injection while no teratomas were identiﬁed upon
histological examination (data not shown).
3.2. Retrospective Analysis of Embryo Progression. Having
established that nonviable ED6 embryos retain the capacity
to give rise to hESC lines, albeit at low frequency, we carried
out a retrospective chart analysis of the morphologicalStem Cells International 5
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Figure 2:CharacterizationofCU1hESCline.ImmunohistochemicalanalysiswithDAPIcounterstainrevealed thathESCcoloniesexpressed
pluripotency markersPOU5F1/OCT4 (a),SSEA-4 (b),TRA1-60 (d), TRA-1-81 (e) (green ﬂuorescence) andwere negative fordiﬀerentiation
marker SSEA-1 (c). hESC cultured as embryoid bodies diﬀerentiated into all three germ layers. Hematoxylin and eosin (f), Masson’s
trichrome (g), immunohistochemistry for neuron-speciﬁc beta-III tubulin (TUJ-1) (h), alpha fetoprotein (AFP) (i), and smooth muscle
actin (SMA) (j) Scale bar = 100µm.
categories in embryos generated for clinical use. Our goal
was to increase the eﬃciency of hESC derivation by the
earlier identiﬁcation (ED5) of embryos that do not improve
further but still have the capacity to give rise to hESC lines.
EmbryoscoringisusedasaprognostictoolinIVFtreatment;
here we compared embryo scores at ED5 with scores at ED6
to assess morphological criteria that would be indicative
of nonviability on ED5. We have analyzed and compared
morphological categories from ED5 and ED6 as cohort
populations since embryos were scored in group culture
rather than individually. From a starting number of 3554
embryos, 446 were transferred or cryopreserved on ED3 and
were not part of further analysis. Of 3108 embryos evaluated
on ED5, 628 were transferred or cryopreserved (all good
qualityembryosmeetingcriteriafortransfer) (Figure 4).The
remaining 2480 embryoswere deemedunsuitable forclinical
useonED5andwerereevaluatedonED6.Uponreevaluation
on ED6, 192 transfer-quality embryos were cryopreserved
while the remaining 2288 embryos were discarded as being
unsuitable for clinical use. Of these, 915 were graded as
blastocysts or hatching blastocysts not of transfer quality
and were thus given grades for overall quality and ICM/TE
quality (Table 1). Most of these embryos were classiﬁed as
poor (898/915; >99%) and only 17/915 (less than 0.02%)
were graded as good or fair quality on ED6. Therefore,
embryo quality at ED5 is highly correlated with embryo
quality at ED6 indicating that criteria for nonviability could
be established at ED5.
4.Discussion
In this study, we derived two new hESC lines from ED6
nonviable embryos with the overall derivation eﬃciency of
1.25%(2/159)forcompactedand/orcavitatedembryos.This
is in line with derivation eﬃciencies previously reported
for nonviable, organismically dead or poor quality embryos:
0.75–2.66%. Not surprisingly, these derivation eﬃciencies
are somewhat lower than derivation successratesfrom viable
blastocysts (6–50% depending on culture conditions) [27,
28].
We have demonstrated that CU1 and CU2 lines show
properties of hESC and diﬀerentiate into derivatives of all
three embryonic germ layers in vitro.H o w e v e r ,d i ﬀeren-
tiation in vivo failed as no teratomas were isolated. This
is in contrast with previous reports of hESC lines derived
from nonviable embryos that were shown to give rise to
diﬀerentiated tissues in vivo [23, 26] but in agreement with
several other studies that have reported lack of teratoma
formation or lack of in vivo diﬀerentiation for lines derived
from embryos of low quality [29–31]. In our case, the failure
of teratoma formation may be due to technical limitations
or could represent a restriction in developmental potential,
although the in vitro diﬀerentiation studies would argue
against the latter explanation. Additional investigation will
be required in order to determine whether failed in vivo
diﬀerentiation or a lower success of teratoma formation
is a property of hESC derived from nonviable embryos.
Nevertheless, hESC lines derived from arrested nonviable
embryos, including those reported here show characteristics
and in vitro diﬀerentiation potential comparable to hESC
derived from surplus viable embryos [23, 26].
Abnormal karyotypes have been reported in hESC after
extended periods of culture, frequently involving chro-
mosomes 12, 17, and X as well as other chromosomes,
including chromosome 18, less frequently [32, 33]. These
chromosomal anomalies are thought to be the result of
adaptive changes that occur with long-term culture. The
low level of mosaicism for monosomy 18 observed in CU2
couldhavearisenduring culture,butbecause itwasobserved
in cells at an early pass number, it could also have been
present in the embryo used to derive the cell line. Although6 Stem Cells International
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Figure 3: Gene expression analysis by qRT-PCR. Expression of pluripotency markers POU5F1/OCT4 (a), SOX2 (b), NANOG (c) and
diﬀerentiation markers BRACHYURY (e), AFP (f), and PAX6 (g) in undiﬀerentiated CU1, CU2, and CHB1 hESC colonies (hESC) and
corresponding embryoid bodies (EmB) harvested on days 4, 8, 14, and 21 (EmBd4, EmBd8, EmBd14, and EmBd21, resp.). Expression levels
were normalized to expression of GAPDH.
Table 1: Quality scores of 915 embryos graded B (blastocysts) or HB (hatching blastocysts) on ED6 and deemed unsuitable for clinical use.
ED6 ICM/TE scorea
ED6 grade AB BB BC BD CB CC CD DB DC DD Total
Good 1 1
Fair 5 1 2 4 1 1 1 16
Poor 1 2 3 223 113 20 76 460 898
Total 1 5 2 2 5 227 113 21 77 461 915
aThe ﬁrst letter represents the quality of the ICM and the second letter the qualityof TE.
a high level of aneuploidy might be expected in arrested or
abnormal embryos, this has generally not been the case in
hESC derived from them (see [26]; this study), indicating
that there are embryos with normal karyotypes, or at least
embryos containing some cells with normal karyotypes,
among poor quality embryos.
By the derivation of CU1, we have demonstrated that
poor quality DC blastocysts on ED6 can retain their capac-
ity to give rise to hESC (Figure 1(a)). The CU2 line origi-
nated from a poor quality ED6 embryo with a small cavity
(Figure 1(b)) which was not given grades for the ICM/TE
quality. From our previous study, we can estimate thatStem Cells International 7
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Figure 4: Comparison of embryo morphology on ED5 and ED6.
MorphologicalcategoriesonED5andED6areshownby percentage
in stacked columns. Numbers indicate the number of embryos in
each category. HB = hatching blastocyst, B = blastocysts, EB = early
blastocyst, comp = compacted, MC = multicell, 1C = onecell, deg =
degenerated.
poor quality cavitated embryos contain between 5 and 64
living cells at ED6 [20]. In our retrospective analysis, we
have focused on further deﬁning criteria of developmental
a r r e s tf o rE D 5e m b r y o st oi m p r o v ed e r i v a t i o ne ﬃciency
from nonviable embryos. Our analysis shows that only a
small proportion of embryos deemed unsuitable for embryo
transfer at ED5 improve to transferable quality by ED6
(192/2480;7.7%).This suggeststhatthe majority ofembryos
could be considered nonviable and that if embryos were
individually cultured, a minimum clinical grade could be
identiﬁed on ED5 that would correlate with lack of viability
on ED6. By targeting derivation eﬀorts on a subgroup of
nonviable embryos that have no potential to improve with
extended in vitro culture and yet could yield hESC lines,
success rates could be increased.
We have observed that published criteria for deeming
embryospoorqualityarequitevariable[31,34–37]ass ev eral
of these reports lacked suﬃcient information to conclude
whether embryos used for derivation had an irreversible loss
of integrated organismic function. Two studies report on
hESC derivation from discarded day 3 embryos with low
morphological scores [34] or poor quality day 3 embryos
[36] that develop into blastocysts after 48 hours culture.
Recently,auniversalminimuminformation(MI)convention
for reporting on hESC derivation was proposed [38, 39]
and used in a study to classify poor quality blastocysts
that subsequently yielded 17 hESC lines [37]. However,
it remains unclear which of the 17 blastocysts were from
cleavage embryos cultured for 48 hours versus thawed
blastocysts and thus from arrested versus surplus embryos.
While information on the quality of an embryo used to
establish hESC lines should be readily available, it would be
practical if the blastocyst grading system proposed in this
MI convention included overall embryo quality scores such
as those employed in IVF clinics. Information on quality of
embryos used for hESC derivation would be pertinent to
eventual therapeutical application in that patients could be
fully informed as to the source of cells used in their therapy.
In summary, we derived and characterized two new
hESC lines from discarded, nonviable ED6 embryos. Our
retrospective studysuggeststhatthegradingsystemcurrently
in use could be employed for the early identiﬁcation of
irreversibly arrested embryos suitable for hESC derivation at
ED5. Embryos with such characteristics could be used for
large-scale derivation of hESC without the destruction of
vital human embryos.
5.Conclusions
Previously, we proposed that the ethical criteria applied to
essential organ donation could be extended to derivation
of hESC lines from embryos with an irreversible loss of
integrated organismic function produced during routine
in vitro fertilization. This study shows the feasibility of
deriving hESC lines from such embryos using standard
grading systems for identiﬁcation of suitable embryos. Eth-
ical considerations and the current legislative climate make
alternative sourcesfor deriving geneticallydiverse hESClines
for research and therapeutic purposes a priority.
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